For the Inventor, By the Inventor

Enter inventor name

Newbury Park, CA, United States of America

Ryan Paul Wurz

USPTO Granted Patents = 27 (Patent Applications = 16)

CIPO Patents = 3 (Patent Applications = 14)

EPO Patents = 10 (Patent Applications = 28)

Average Co-Inventor Count = 7.9

ph-index = 11

Forward Citations = 282(Granted Patents)

Location History:

Mewbury Park, CA (US) (2021)
Newbury Park, CA (US) (2010 - 2024)
Thousand Oaks, CA (US) (2019 - 2024)

Company Filing History:

27 out of 1,970

Teijin Pharma Limited

where one patent can have more than one assignee

Years Active: 2010-2025

where 'Filed Patents' based on already Granted Patents

27 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12440491 - KRAS G12C inhibitors and methods of using the same (2025-10-14),

2. 12083121 - Substituted piperazines as KRAS G12C inhibitors (2024-09-10),

3. 11993597 - Inhibitors of KRAS G12C and methods of using the same (2024-05-28),

4. 11905281 - KRAS G12C inhibitors and methods of using the same (2024-02-20),

5. 11766436 - KRAS G12C inhibitors and methods of using the same (2023-09-26),

6. 11306087 - Inhibitors of KRAS G12C and methods of using the same (2022-04-19),

7. 11285156 - Substituted piperazines as KRAS G12C inhibitors (2022-03-29),

8. 11096939 - KRAS G12C inhibitors and methods of using the same (2021-08-24),

9. 11090304 - KRAS G12C inhibitors and methods of using the same (2021-08-17),

10. 11053226 - KRAS G12C inhibitors and methods of using the same (2021-07-06),

11. 11045484 - KRAS G12C inhibitors and methods of using the same (2021-06-29),

12. 10988485 - KRAS G12C inhibitors and methods of using the same (2021-04-27),

13. 10640504 - Inhibitors of KRAS G12C and methods of using the same (2020-05-05),

14. 10519146 - KRAS G12C inhibitors and methods of using the same (2019-12-31),

15. 9394297 - Amides as pim inhibitors (2016-07-19),

Title: Innovations by Ryan Paul Wurz: A Trailblazer in Cancer Treatment

Introduction

Ryan Paul Wurz, based in Newbury Park, CA, is a prominent inventor recognized for his groundbreaking contributions to the field of cancer treatments. With an impressive portfolio of 26 patents, Wurz has made significant strides in developing innovative therapies aimed at combating serious disorders, particularly various types of cancer.

Latest Patents

Among his latest achievements are the patents related to Substituted Piperazines as KRAS G12C Inhibitors. These inventions detail compositions and methods for utilizing KRAS G12C inhibitors, which are invaluable for treating pancreatic, colorectal, and lung cancers. His work continues to push the boundaries of cancer research, offering hope for effective treatment options for patients afflicted by these diseases.

Career Highlights

Wurz's professional journey includes significant roles in leading biotechnology companies such as Amgen Inc. and Teijin Pharma Limited. His dedication to advancing medical science through innovative treatments has positioned him as a key player in the pharmaceutical industry.

Collaborations

Throughout his career, Ryan Paul Wurz has collaborated with esteemed colleagues, including Victor J Cee and Brian Alan Lanman. These partnerships have fostered a creative environment for innovation, enabling the development of cutting-edge solutions in cancer therapy.

Conclusion

Ryan Paul Wurz exemplifies the spirit of innovation and dedication in the realm of medical sciences. His contributions to cancer treatment through his patents signify not just personal achievement but also a considerable advancement in therapeutic options for millions. With his ongoing work, the future looks promising for cancer research and treatment methodologies.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…